Psychedelic Beacon
DFTXNASDAQPhase 3

Definium Therapeutics

DT120 · LSD (lysergide d-tartrate) · Generalized Anxiety Disorder

Company Overview

Definium Therapeutics (formerly MindMed, rebranded January 9, 2026) is a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies. Their lead program DT120 (formerly MM120), a pharmaceutical-grade d-tartrate salt of LSD, received FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder. DT120 Phase 2b was completed and published in JAMA in October 2025. Four Phase 3 trials are enrolling or planned: Voyage (GAD, topline Q2 2026), Panorama (GAD, topline H2 2026), Emerge (MDD, topline mid-2026), and ASCEND (second MDD study, ~175 participants, planned mid-2026). Definium is one of the best-capitalized companies in the psychedelic space.

Pipeline

Drug / CompoundStageIndication
DT120
LSD d-tartrate (lysergide d-tartrate)
Phase 3Generalized Anxiety Disorder
DT120
LSD d-tartrate (lysergide d-tartrate)
Phase 3Major Depressive Disorder
DT120
LSD d-tartrate (lysergide d-tartrate)
Phase 3Major Depressive Disorder
DT402
R-MDMA (rectus enantiomer of MDMA)
Phase 2aAutism Spectrum Disorder

Key Financials

Cash Position
$412M
Burn Rate
~$20-40M/quarter
Last Reported
Q3 2025

Financial data is approximate. Always verify with official SEC filings.

Upcoming Catalysts

  1. Q2 2026
    Voyage Phase 3 topline readout for DT120 in Generalized Anxiety Disorder
    Clinical
  2. Mid-2026
    Emerge Phase 3 topline readout for DT120 in Major Depressive Disorder
    Clinical
  3. H2 2026
    Panorama Phase 3 topline readout for DT120 in Generalized Anxiety Disorder
    Clinical
  4. Mid-2026
    ASCEND Phase 3 trial initiation for DT120 in MDD (~175 participants)
    Clinical

Recent News

  • 2026-01MindMed rebrands as Definium Therapeutics, trades as DFTX; four Phase 3 DT120 trials enrolling or planned
  • 2025-10MindMed MM120 Phase 2b results published in JAMA, showing durable GAD response

News items are manually curated from public company press releases.

Looking for psychedelic therapy?

Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.

Browse Clinic Directory →

Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.